Peripheral Artery Disease Management

Initial Management

The European Society of Cardiology recommends initial management of peripheral artery disease to include supervised exercise therapy, antiplatelet therapy, statin medication, risk factor modification, and smoking cessation, with revascularization considered only after a 3-month trial of optimal medical therapy in patients with persistent lifestyle-limiting symptoms 1, 2

The American College of Cardiology recommends all patients with PAD receive aggressive cardiovascular risk factor modification to reduce morbidity and mortality, including statin therapy to achieve an LDL-C target of <100 mg/dL 1, 3
The American College of Cardiology recommends antihypertensive therapy to target blood pressure <140/90 mmHg in most patients, or <130/80 mmHg in those with diabetes or chronic kidney disease 3, 4
The American College of Cardiology recommends glucose control to target hemoglobin A1C <7% to reduce microvascular complications in patients with diabetes and PAD 3, 4

The European Society of Cardiology recommends a supervised exercise training program as first-line treatment for patients with intermittent claudication, with exercise sessions performed at least 3 times per week for a minimum of 30 minutes per session, for at least 12 weeks 1, 5, 6
Walking to moderate-severe claudication pain may improve walking performance, though improvements can also be achieved with lesser pain severities 1

The American College of Cardiology recommends antiplatelet therapy to reduce the risk of myocardial infarction, stroke, and vascular death in symptomatic PAD patients, with clopidogrel (75 mg daily) as the preferred antiplatelet agent 5, 6
The American College of Cardiology recommends aspirin (75-100 mg daily) as an alternative to clopidogrel for reducing cardiovascular events in symptomatic PAD patients 5, 6

The European Society of Cardiology recommends revascularization only after a 3-month trial of optimal medical therapy and exercise therapy in patients with persistent lifestyle-limiting symptoms and impaired quality of life 1
The European Society of Cardiology recommends the mode and type of revascularization to be adapted to anatomical lesion location, lesion morphology, and general patient condition 1

The European Society of Cardiology recommends regular follow-up at least once a year to assess clinical and functional status, medication adherence, limb symptoms, and cardiovascular risk factors 1, 2

The European Society of Cardiology recommends early recognition of CLTI and prompt referral to a vascular team for limb salvage, with revascularization to be performed as soon as possible in CLTI patients 1

Supervised exercise training should be performed for a minimum of 30-45 minutes, at least 3 times per week for a minimum of 12 weeks as the initial management strategy for patients with intermittent claudication 7, 8
The American College of Cardiology and American Heart Association (ACC/AHA) guidelines strongly recommend (Class I, Level of Evidence A) supervised exercise programs to improve functional status, quality of life, and reduce leg symptoms 8
A supervised exercise program should be discussed as a treatment option for claudication before considering pharmacological interventions or revascularization 8

Antiplatelet therapy is recommended to reduce cardiovascular risk in patients with PAD, but should be initiated after or alongside the exercise program, not as a replacement for it 9
Clopidogrel (75 mg daily) is the preferred antiplatelet agent for reducing the risk of myocardial infarction, stroke, or vascular death in patients with symptomatic PAD 9
For patients with an ABI of 0.8, antiplatelet therapy is indicated (Class IIa recommendation) to reduce cardiovascular events, but this should not replace exercise therapy 9

The effectiveness of unsupervised exercise programs is not well established as an initial treatment modality (Class IIb, Level of Evidence B) 7

Cilostazol (100 mg twice daily) can be considered as an adjunctive therapy to improve walking distance if exercise therapy alone is insufficient (Class I, Level of Evidence A) 7
Pentoxifylline may be considered as a second-line alternative to cilostazol, though its clinical effectiveness is marginal (Class IIb) 7